A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

  1. Dawson, M.A.
  2. Borthakur, G.
  3. Huntly, B.J.P.
  4. Karadimitris, A.
  5. Alegre, A.
  6. Chaidos, A.
  7. Vogl, D.T.
  8. Pollyea, D.A.
  9. Davies, F.E.
  10. Morgan, G.J.
  11. Glass, J.L.
  12. Kamdar, M.
  13. Mateos, M.-V.
  14. Tovar, N.
  15. Yeh, P.
  16. Delgado, R.G.
  17. Basheer, F.
  18. Marando, L.
  19. Gallipoli, P.
  20. Wyce, A.
  21. Krishnatry, A.S.
  22. Barbash, O.
  23. Bakirtzi, E.
  24. Ferron-Brady, G.
  25. Karpinich, N.O.
  26. McCabe, M.T.
  27. Foley, S.W.
  28. Horner, T.
  29. Dhar, A.
  30. Kremer, B.E.
  31. Dickinson, M.
  32. Montrer des auteurs +
Revue:
Clinical cancer research : an official journal of the American Association for Cancer Research

ISSN: 1557-3265

Année de publication: 2023

Volumen: 29

Número: 4

Pages: 711-722

Type: Article

DOI: 10.1158/1078-0432.CCR-22-1284 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus